Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Acusphere, Inc. is a pharmaceutical firm specializing in the creation and market launch of cardiovascular treatments. Its flagship product is Imagify (perflubutane polymer microspheres), a cardiovascular medication designed to assess myocardial perfusion and aid in the diagnosis of coronary artery disease. This drug is administered as an injectable suspension. Initially established as Polymers For Medicine, Inc., the organization rebranded as Acusphere, Inc. in March 2004. Founded in 1993, the company maintains its headquarters in Watertown, Massachusetts.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is undervalued on EV/EBITDA.